The emerging role of CDK4/6i in HER2-positive breast cancer

Ciara C. O’Sullivan, Vera J. Suman, Matthew P. Goetz

Research output: Contribution to journalReview article

Abstract

Prior to the advent of the monoclonal antibody trastuzumab, human epidermal growth-factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) was associated with an aggressive clinical course and poor survival outcomes. In the era of effective HER2-directed therapies, median survival rates for patients with metastatic HER2+ BC now approach 5 years. Despite these improvements, the majority of affected patients unfortunately die from disease. Therapies to overcome treatment resistance are being actively pursued. One strategy has been to target the cyclin-dependent kinases 4/6 (CDK4/6), as they are downstream of HER2 and many of the cellular pathways driving resistance to HER2-targeted therapies, and play a key role in proliferation by controlling transition through the G1 restriction point to the S phase of the cell cycle. In this article, we review the published literature with regard to the rationale for CDK4/6-directed therapies in HER2+ BC and discuss ongoing clinical research and new challenges in the field.

Original languageEnglish (US)
JournalTherapeutic Advances in Medical Oncology
Volume11
DOIs
StatePublished - Jan 1 2019

Fingerprint

Breast Neoplasms
Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 4
Play Therapy
G1 Phase Cell Cycle Checkpoints
Therapeutics
human ERBB2 protein
S Phase
Cell Cycle
Survival Rate
Monoclonal Antibodies
Survival
Research

Keywords

  • breast cancer
  • CDK4/6 inhibitor
  • HER2+ breast cancer
  • HER2-targeted therapy
  • metastasis

ASJC Scopus subject areas

  • Oncology

Cite this

The emerging role of CDK4/6i in HER2-positive breast cancer. / O’Sullivan, Ciara C.; Suman, Vera J.; Goetz, Matthew P.

In: Therapeutic Advances in Medical Oncology, Vol. 11, 01.01.2019.

Research output: Contribution to journalReview article

@article{b32f32881ba247d689319cee62011e6c,
title = "The emerging role of CDK4/6i in HER2-positive breast cancer",
abstract = "Prior to the advent of the monoclonal antibody trastuzumab, human epidermal growth-factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) was associated with an aggressive clinical course and poor survival outcomes. In the era of effective HER2-directed therapies, median survival rates for patients with metastatic HER2+ BC now approach 5 years. Despite these improvements, the majority of affected patients unfortunately die from disease. Therapies to overcome treatment resistance are being actively pursued. One strategy has been to target the cyclin-dependent kinases 4/6 (CDK4/6), as they are downstream of HER2 and many of the cellular pathways driving resistance to HER2-targeted therapies, and play a key role in proliferation by controlling transition through the G1 restriction point to the S phase of the cell cycle. In this article, we review the published literature with regard to the rationale for CDK4/6-directed therapies in HER2+ BC and discuss ongoing clinical research and new challenges in the field.",
keywords = "breast cancer, CDK4/6 inhibitor, HER2+ breast cancer, HER2-targeted therapy, metastasis",
author = "O’Sullivan, {Ciara C.} and Suman, {Vera J.} and Goetz, {Matthew P.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1758835919887665",
language = "English (US)",
volume = "11",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - The emerging role of CDK4/6i in HER2-positive breast cancer

AU - O’Sullivan, Ciara C.

AU - Suman, Vera J.

AU - Goetz, Matthew P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Prior to the advent of the monoclonal antibody trastuzumab, human epidermal growth-factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) was associated with an aggressive clinical course and poor survival outcomes. In the era of effective HER2-directed therapies, median survival rates for patients with metastatic HER2+ BC now approach 5 years. Despite these improvements, the majority of affected patients unfortunately die from disease. Therapies to overcome treatment resistance are being actively pursued. One strategy has been to target the cyclin-dependent kinases 4/6 (CDK4/6), as they are downstream of HER2 and many of the cellular pathways driving resistance to HER2-targeted therapies, and play a key role in proliferation by controlling transition through the G1 restriction point to the S phase of the cell cycle. In this article, we review the published literature with regard to the rationale for CDK4/6-directed therapies in HER2+ BC and discuss ongoing clinical research and new challenges in the field.

AB - Prior to the advent of the monoclonal antibody trastuzumab, human epidermal growth-factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) was associated with an aggressive clinical course and poor survival outcomes. In the era of effective HER2-directed therapies, median survival rates for patients with metastatic HER2+ BC now approach 5 years. Despite these improvements, the majority of affected patients unfortunately die from disease. Therapies to overcome treatment resistance are being actively pursued. One strategy has been to target the cyclin-dependent kinases 4/6 (CDK4/6), as they are downstream of HER2 and many of the cellular pathways driving resistance to HER2-targeted therapies, and play a key role in proliferation by controlling transition through the G1 restriction point to the S phase of the cell cycle. In this article, we review the published literature with regard to the rationale for CDK4/6-directed therapies in HER2+ BC and discuss ongoing clinical research and new challenges in the field.

KW - breast cancer

KW - CDK4/6 inhibitor

KW - HER2+ breast cancer

KW - HER2-targeted therapy

KW - metastasis

UR - http://www.scopus.com/inward/record.url?scp=85075660835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075660835&partnerID=8YFLogxK

U2 - 10.1177/1758835919887665

DO - 10.1177/1758835919887665

M3 - Review article

AN - SCOPUS:85075660835

VL - 11

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

ER -